Molecular landscape of borderline ovarian tumours: A systematic review

被引：1
作者：
Sadlecki, Pawel [1 ,2 ]
Walentowicz-Sadlecka, Malgorzata [1 ,2 ]
机构：
[1] Univ Sci & Technol, Med Dept, Bydgoszcz, Poland
[2] Reg Polyclin Hosp, Dept Obstet & Gynecol, Grudziadz, Poland
来源：
OPEN MEDICINE | 2024年 / 19卷 / 01期
关键词：
borderline ovarian tumours; molecular features; mutations; genetic mutations; BRAF; KRAS; NRAS; ARID1A; CADM1; PIK3CA; CHEK2; CLAUDIN-1; ERBB2; loss of heterozygosity; PTEN; microsatellite instability; B-CATENIN; E-CADHERIN; BRCA; 1; 2; MICROSATELLITE INSTABILITY; EXPRESSION PATTERNS; BRAF MUTATIONS; ADVANCED-STAGE; CANCER; ENDOMETRIOSIS; PATHOGENESIS; CELL; PROGRESSION; DISCOVERY;
D O I：
10.1515/med-2024-0976
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Borderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their significance in the context of the overall therapeutic approach. The systematic review included articles published between 2000 and 2023 in the databases: PubMed, EMBASE, and Cochrane. After a detailed analysis of the available publications, we qualified for the systematic review: 28 publications on proto-oncogenes: BRAF, KRAS, NRAS, ERBB2, and PIK3CA, 20 publications on tumour suppressor genes: BRCA1/2, ARID1A, CHEK2, PTEN, 4 on adhesion molecules: CADM1, 8 on proteins: B-catenin, claudin-1, and 5 on glycoproteins: E-Cadherin. In addition, in the further part of the systematic review, we included eight publications on microsatellite instability and three describing loss of heterozygosity in BOT. Molecular changes found in BOTs can vary on a case-by-case basis, identifying carcinogenic mutations through molecular analysis and developing targeted therapies represent significant advancements in the diagnosis and treatment of ovarian malignancies. Molecular studies have contributed significantly to our understanding of BOT pathogenesis, but substantial research is still required to elucidate the relationship between ovarian neoplasms and extraneous disease, identify accurate prognostic indicators, and develop targeted therapeutic approaches.
引用
收藏
页数：17
相关论文
共 98 条
  • [1] Needleoscopic Conservative Staging of Borderline Ovarian Tumor
    Alletti, Salvatore Gueli
    Rossitto, Cristiano
    Perrone, Emanuele
    Cianci, Stefano
    De Blasis, Ilaria
    Fagotti, Anna
    Scambia, Giovanni
    [J]. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2017, 24 (04) : 529 - 530
  • [2] Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
    Altamura, Concetta
    Greco, Maria Raffaella
    Carratu, Maria Rosaria
    Cardone, Rosa Angela
    Desaphy, Jean-Francois
    [J]. CANCERS, 2021, 13 (04) : 1 - 28
  • [3] ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
    Arteaga, Carlos L.
    Engelman, Jeffrey A.
    [J]. CANCER CELL, 2014, 25 (03) : 282 - 303
  • [4] Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma
    Ayhan, Ayse
    Mao, Tsui-Lien
    Seckin, Tamer
    Wu, Chen-Hsuan
    Guan, Bin
    Ogawa, Hiroshi
    Futagami, Masayuki
    Mizukami, Hiroki
    Yokoyama, Yoshihito
    Kurman, Robert J.
    Shih, Ie-Ming
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (08) : 1310 - 1315
  • [5] Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2010.04.024, 10.1053/j.gastro.2009.12.064]
  • [6] Casla MS, 2003, ANTICANCER RES, V23, P5139
  • [7] The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
    Chen, Yungchang
    Sun, Hao
    Deng, Yanhong
    Ma, Yutong
    Huang, He
    Liu, Yang
    Zhang, Yaru
    Zhang, Hongyu
    Ye, Sheng
    Mingyan, E.
    Guo, Hongqiang
    Wu, Mengmeng
    Wu, Chunman
    Pu, Xingxiang
    Chen, Xinggui
    Liang, Chaoyong
    Ou, Qiuxiang
    Weng, Huawei
    Wu, Xue
    Shao, Yang
    Gu, Anxin
    Lin, Tongyu
    [J]. BIOMARKER RESEARCH, 2023, 11 (01)
  • [8] Chui M Herman, 2019, Oncotarget, V10, P6870, DOI 10.18632/oncotarget.27326
  • [9] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    Colombo, N.
    Sessa, C.
    du Bois, A.
    Ledermann, J.
    McCluggage, W. G.
    McNeish, I.
    Morice, P.
    Pignata, S.
    Ray-Coquard, I.
    Vergote, I.
    Baert, T.
    Belaroussi, I.
    Dashora, A.
    Olbrecht, S.
    Planchamp, F.
    Querleu, D.
    Baert, T.
    Banerjee, S.
    Belaroussi, I.
    Blecharz, P.
    Bruchim, I.
    Cibula, D.
    Colombo, N.
    Concin, N.
    Davidson, B.
    Dashora, A.
    Devouassoux-Shisheboran, M.
    du Bois, A.
    Ferrero, A.
    Glasspool, R.
    Gonzalez-Martin, A.
    Heinzelmann-Schwarz, V.
    Joly, F.
    Kim, J. W.
    Kridelka, F.
    Ledermann, J.
    Lorusso, D.
    Mahner, S.
    McCluggage, W. G.
    McNeish, I.
    Mikami, M.
    Mirza, M. R.
    Morice, P.
    Nicum, S.
    Olbrecht, S.
    O'Donnell, D. M.
    Pautier, P.
    Planchamp, F.
    Pignata, S.
    Querleu, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 672 - 705
  • [10] PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer
    Csolle, Mariah P.
    Ooms, Lisa M.
    Papa, Antonella
    Mitchell, Christina A.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 23
12345678910